

1 Integrated NMR and MS analysis of plasma metabolome reveals
2 major changes in inflammatory markers, one-carbon, lipid, and
3 amino acid metabolism in severe and fatal COVID-19 subjects

4
5 *Marcos C. Gama-Almeida¹, Livia Teixeira², Eugenio D. Hottz³, Paula Ivens⁴, Hygor Ribeiro^{4,5},*
6 *Gabriela D. A. Pinto¹, Rafael Garrett⁴, Alexandre G. Torres^{1,5}, Talita I. A. Carneiro¹, Bianca de*
7 *O. Barbalho¹, Christian Ludwig⁶, Claudio J. Struchiner^{7,8}, Iranaia Assunção-Miranda⁹, Ana*
8 *Paula C. Valente¹⁰, Fernando A. Bozza^{11,12}, Patricia T. Bozza², Gilson C. dos Santos Jr^{13*}, Tatiana*
9 *El-Bacha^{1,5*}*

10 ¹ LeBioME-Bioactives, Mitochondrial and Placental Metabolism Core, Institute of Nutrition
11 Josué de Castro, Universidade Federal do Rio de Janeiro, RJ-Brazil;

12 ² Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, RJ,
13 Brazil;

14 ³ Laboratory of Immunothrombosis, Department of Biochemistry, Federal University of Juiz de
15 Fora, Juiz de Fora, Brazil;

16 ⁴ LabMeta, Metabolomics Laboratory, Institute of Chemistry, Universidade Federal do Rio de
17 Janeiro, RJ, Brazil;

18 ⁵ Lipid Biochemistry and Lipidomics Laboratory, Department of Chemistry, Universidade
19 Federal do Rio de Janeiro, RJ, Brazil;

20 ⁶ Institute of Metabolism and Systems research, University of Birmingham, Birmingham, United
21 Kingdom;

22 ⁷ School of Applied Mathematics, Fundação Getúlio Vargas, RJ, Brazil;

23 ⁸ Institute of Social Medicine, Universidade do Estado do Rio de Janeiro, RJ, Brazil;

24 ⁹ LaRIV, Instituto de Microbiologia Paulo de Goes, Universidade Federal do Rio de Janeiro, RJ,
25 Brazil;

26 ¹⁰ National Center for Nuclear Magnetic Resonance - Jiri Jonas, Institute of Medical
27 Biochemistry, Universidade Federal do Rio de Janeiro, RJ, Brazil;

28 ¹¹ National Institute of infectious disease Evandro Chagas, Oswaldo Cruz Foundation, RJ, Brazil;

29 ¹²D'Or institute for Research and Education, RJ, Brazil.

30 ¹³LabMet- Laboratory of Metabolomics, IBRAG, Department of Genetics, State University of
31 Rio de Janeiro, RJ, Brazil.

32

33 Short title: one-carbon, lipid and amino acid metabolism dysregulation in severe and fatal

34 COVID-19

35 KEYWORDS: SARS-CoV-2, metabolomics, ¹H-NMR, high-resolution mass spectrometry, fatal

36 COVID-19, virus-host interactions, metabolic alterations, sex differences.

37

38 ***Corresponding authors:** gilson.junior@uerj.br; tatiana@nutricao.ufrj.br

39

40

41 **Abstract**

42 Brazil has the second highest COVID-19 death rate while Rio de Janeiro is among the states with
43 the highest rate in the country. Although effective vaccines have been developed, it is anticipated
44 that the ongoing COVID-19 pandemic will transition into an endemic state. Under this scenario, it
45 is worrisome that the underlying molecular mechanisms associated with the disease clinical
46 evolution from mild to severe, as well as the mechanisms leading to long COVID are not yet fully
47 understood. In this study, ¹H Nuclear Magnetic Resonance spectroscopy and Liquid
48 Chromatography-Mass spectrometry-based metabolomics were used to identify potential
49 pathways and metabolites involved in COVID-19 pathophysiology and disease outcome. We
50 prospectively enrolled 35 severe RT-PCR confirmed COVID-19 cases within 72 hours from
51 intensive care unit admission, between April and July 2020 from two reference centers in Rio de
52 Janeiro, and 12 samples from non-infected control subjects. Of the 35 samples from COVID-19
53 patients, 18 were from survivors and 17 from non-survivors. We observed that patients with severe
54 COVID-19 had their plasma metabolome significantly changed if compared to control subjects.
55 We observed lower levels of glycerophosphocholine and other choline-related metabolites, serine,
56 glycine, and betaine, indicating a dysregulation in methyl donors and one-carbon metabolism.
57 Importantly, non-survivors had higher levels of creatine/creatinine, 4-hydroxyproline, gluconic
58 acid and *N*-acetylserine compared to survivors and controls, reflecting uncontrolled inflammation,
59 liver and kidney dysfunction, and insulin resistance in these patients. Lipoprotein dynamics and
60 amino acid metabolism were also altered in severe COVID-19 subjects. Several changes were
61 greater in women, thus patient's sex should be considered in pandemic surveillance to achieve
62 better disease stratification and improve outcomes. The incidence of severe outcome after hospital

63 discharge is very high in Brazil, thus these metabolic alterations may be used to monitor patients'
64 organs and tissues and to understand the pathophysiology of long-post COVID-19.

65

66 **Introduction**

67 The existing vaccines for SARS-CoV-2 infection resulted in a significant reduction in the number
68 of severe cases of the disease. However, it is anticipated that the ongoing coronavirus disease 2019
69 (COVID-19) pandemic will transition into an endemic state [1]. By the time this article is being
70 written, COVID-19 has exceeded 762 million cases with almost 6.9 million deaths worldwide [2].
71 Brazil has recorded more than 700,000 deaths, making it the country with the second highest
72 number of deaths worldwide [2]. Rio de Janeiro, where this study took place, had 2.79 million
73 confirmed cases with approximately 77,000 deaths. The state is among the ones with the highest
74 mortality rate [3].

75 The replication of SARS-CoV-2 triggers a systemic immune response that leads to tissue damage
76 and reprogramming of whole-body metabolism [4,5]. Additionally, around 20 % of infected
77 subjects may experience long-term symptoms after recovery from the initial illness [6], a condition
78 that is associated with neurological, gastrointestinal, pulmonary, and cardiovascular alterations
79 and which can be highly debilitating [7]. Even patients who present mild symptoms in the acute
80 phase of the disease may later develop post-COVID symptoms [8].

81 These observations reveal the complexity of COVID-19 pathophysiology and its profound impact
82 on different tissues and cells. However, the underlying molecular mechanisms associated with the
83 disease clinical evolution from mild to severe, as well as the mechanisms leading to long COVID-
84 19 symptoms are not yet known. The complex multisystemic nature of SARS-CoV-2 infection

85 calls for a system-level approach to help us better understand the underlying molecular
86 mechanisms associated with the condition.

87 Metabolomics is the central omics in information translation [9] by providing the metabolic
88 signature of organs and biological fluids in different conditions and may help elucidate the
89 metabolic pathways associated with SARS-CoV-2 infectious process. We and others have shown
90 that metabolomics was essential in the development of new approaches that improved the
91 understanding and treatment of emerging viral diseases such as Dengue [10,11], Chikungunya
92 [10], SARS [12], and Zika [13,14]. Alterations in host energy, amino acid and lipid metabolism
93 are frequently observed in viral infections, as the virus disturbs and exploits host metabolic
94 pathways for its own benefit [15,16]. These metabolic alterations have a critical role in disease
95 outcome and in modulating the host immune response.

96 The modulation of host lipid metabolism is a feature shared by coronaviruses and is essential for
97 viral RNA replication [17], as it enables the viral envelope membrane, as well as double-membrane
98 vesicles and lipid compartments to be synthesized. Indeed, our group has shown that lipid droplets
99 accumulate in monocytes isolated from COVID-19 subjects and serve as an assembly platform for
100 SARS-CoV-2 particles [18]. The orchestrate of lipid flow within different cell compartments by
101 the SARS-CoV-2 non-structural protein 6 (NSP6) ensures the proper organization of double-
102 membrane vesicles, as well as their effective communication with lipid droplets [19]. All these
103 events are essential for SARS-CoV-2 replication.

104 One of the first studies to use a multi-omics approach to gain insight into the pathophysiology of
105 COVID-19 was done by Shen *et al.* with a small cohort of patients. In the study, proteomics and
106 metabolomics approaches revealed that mild and severe COVID-19 patients presented metabolic
107 and immune dysregulation [20]. More than 100 lipid species, including glycerophospholipids, fatty

108 acids, and lipoproteins, and several amino acids, were downregulated in sera from subjects infected
109 with SARS-CoV-2, if compared to controls [20]. Alterations in lipoproteins using NMR-
110 metabolomics were also confirmed in larger cohorts [21] and single-cell metabolomics of
111 monocytes reinforced the idea that modulation of intermediary metabolism, in particular organic
112 acids, plays crucial roles in COVID-19 severity [22]. Regarding the modulation of amino acid
113 metabolism, several studies have reported that patients have low levels of plasma tryptophan, being
114 now considered a marker for the extent of inflammation and COVID-19 severity [20, 23-25].
115 Additionally, it has been reported that COVID-19 in-patients show dysregulation in the
116 metabolism of methyl donors, including higher levels of S-adenosyl-homocysteine and lower
117 levels of homocysteine, regardless of IL-6 levels [26]. Indeed, SARS-CoV-2 genome replication
118 seems to depend on folate and methionine cycles modulation [27]. Therefore, SARS-CoV-2
119 infection is thought to affect various aspects of host metabolism and the extent of these changes is
120 believed to be linked to the severity of the disease. On the other hand, the specific metabolic
121 differences that may distinguish the severe cases of COVID-19 from those that are fatal have not
122 yet been fully addressed.

123 In this study, we used ¹H Nuclear Magnetic Resonance (NMR) spectroscopy and Liquid
124 Chromatography-High-Resolution-Mass spectrometry (LC-HRMS)-based metabolomics to
125 perform a thorough investigation of the metabolic disturbances induced by SARS-CoV-2 infection
126 in a well characterized prospective cohort of subjects with severe COVID-19, including survivors
127 and non-survivors, and healthy subjects. Patients' samples were collected in Rio de Janeiro, Brazil,
128 between April and July 2020. We were particularly interested in investigating metabolites
129 associated with one-carbon metabolism and with lipid and amino acid metabolism.

130 The incidence of severe outcome after hospital discharge is very high in Brazil, thus these
131 metabolic alterations may be used to monitor patients' organs and tissues and to understand the
132 pathophysiology of long-post COVID-19.

133 **Materials and Methods**

134 **Study design and Participants**

135 We prospectively enrolled severe RT-PCR confirmed cases within 72 hours from intensive care
136 unit (ICU) admission in two reference centers at the Instituto Estadual do Cérebro Paulo Niemeyer
137 and Hospital Copa Star, Rio de Janeiro, Brazil between April and July 2020. Adults (≥ 18 years of
138 age) with severe COVID-19 (n=35) were enrolled in this study. Patients' clinical status was
139 confirmed by presence of chest infiltrates on computed tomography scan and by the need of
140 respiratory support with either non-invasive oxygen supplementation or mechanical ventilation.
141 The complete clinical information was collected prospectively using a standardized form:
142 International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)/World
143 Health Organization (WHO) Clinical Characterization Protocol for Severe Emerging Infections
144 (CCP-BR). Upon admission, clinical and laboratory data were recorded for all severe patients
145 included in the study. The primary outcome analyzed was 28-day mortality, and patients were
146 classified as survivors (n=18) or non-survivors (n=17).

147 All ICU-admitted patients received the usual supportive care for severe COVID-19. Patients with
148 acute respiratory distress syndrome (ARDS) were managed with neuromuscular blockade and a
149 protective ventilation strategy that included low tidal volume (6 mL/kg predicted body weight)
150 and limited driving pressure (< 16 cmH₂O) as well as optimal positive end-expiratory pressure

151 calculated based on the best lung compliance and PaO₂/fraction of inspired oxygen (FiO₂) ratio.
152 Antithrombotic prophylaxis was performed with 40 to 60 mg of enoxaparin per day. Patients did
153 not receive antivirals, steroids, or other anti-inflammatory or antiplatelet drugs.

154 Peripheral blood was also collected from SARS-CoV-2 negative participants (control group; n=12)
155 confirmed by RT-PCR of swabs on the day of blood sampling. The control group included subjects
156 of matching age and sex distribution compared to infected subjects. These participants were not
157 under anti-inflammatory or antiplatelet drugs for at least 2 weeks prior the study.

158 The National Review Board of Brazil approved the study protocol (Comissão Nacional de Ética
159 em Pesquisa [CONEP] 30650420.4.1001.0008), and informed consent was obtained from all
160 subjects or their caregivers.

161 **Chemicals and solvents**

162 All solvents used were of HPLC analytical grade. Acetonitrile and methanol were obtained from
163 TEDIA® (Fairfield, USA) and isopropanol from Sigma Aldrich (São Paulo, Brazil). Water was
164 purified in the Milli-Q device, Millipore Purification System (Billerica, MA, USA). Mobile phase
165 additives formic acid and ammonium hydroxide were purchased from TEDIA® and ammonium
166 acetate was obtained from J. T. Baker® (Brazil). Isotopically labelled internal standards U¹³C D-
167 glucose and U¹³C L-glutamine and deuterium oxide were purchased from Cambridge Isotope
168 Laboratories, Inc. (MA, USA). All other standards were obtained from Sigma Aldrich.

169

170

171 **Sample processing**

172 Blood samples were drawn into acid-citrate-dextrose and centrifuged (200 × g, 20 minutes, room
173 temperature). Plasma was collected and stored at -80°C until analysis. Citrate-dextrose buffer was
174 chosen to preserve platelets. This choice of buffer prevented us from comparing citrate and sugars
175 among groups and limited the identification of metabolites that present chemical shifts in the ¹H
176 NMR spectrum, which is in the proximity of citrate.

177 **Nuclear Magnetic Resonance-based metabolomics**

178 **Sample preparation**

179 Frozen plasma samples were quickly thawed and diluted 3-fold in sodium phosphate buffer and
180 deuterium oxide (final concentration 50 mM phosphate buffer and 10 % deuterium oxide, pH 7.4).
181 A total of 600 μL of diluted samples were transferred to a 5 mm NMR tube.

182 **NMR acquisition and spectra pre-processing and metabolite assignment**

183 NMR spectra were acquired on a Bruker Advance III 500.13 MHz at 300 K, coupled with a cooled
184 automatic sample case at 280 K. 1D-¹H NMR spectra were acquired using excitation sculpting to
185 suppress the solvent signal [28] as well as a CPMG (Carr-Purcell-Meiboom-Gill) T2 filter [29]
186 with 32 loop counters and delay of 0.001 s. 32768 complex data points were acquired per transient
187 with a total of 1024 transients. The spectral width was set to 19.99 ppm, resulting in an acquisition
188 time of 3.27 s per FID. The relaxation delay was set to 1.74 s.

189 Spectra data were pre-processed in the MetaboLab [30] software. Prior to Fourier transform, the
190 FIDs were apodised using an exponential window-function with 0.3 Hz line-broadening and then
191 zero-filled to 65536 data points. After Fourier transform, each spectrum was manually phase
192 corrected, followed by a spline-baseline correction. Finally, all spectra were referenced to the
193 signal of the ^1H linked to the anomeric carbon of glucose. Baseline noise and regions
194 corresponding to water and citrate signals were deleted. Spectra data were binned with 0.005 ppm
195 interval and transformed by the generalized logarithm function [31]. The resulting table presented
196 81,498 data points, corresponding to metabolites' intensities.

197 Following 2D spectra, HSQC ^1H - ^{13}C and TOCSY ^1H - ^1H , acquisition, data was uploaded on the
198 COLMAR [32,33] for the assignments. We also overlaid spectra from the BMRB [34] and HMDB
199 4.0 [35] databank. The software ICON NMR (Bruker) was used for automatic acquisition.

200 **Mass spectrometry-based metabolomics**

201 **Standards**

202 A stock of internal standard (IS) solution was prepared with a final concentration of 0.15 mg mL⁻¹
203 ¹ for U- ^{13}C D-glucose and 0.13 mg mL⁻¹ for U- ^{13}C L-glutamine in acetonitrile/isopropanol/water
204 (3:3:2, % v/v/v).

205 Stock solutions of targeted analytes (Supplementary Tables 1 and 2) were prepared at 1.0 mg mL⁻¹
206 in methanol or in different proportions of acetonitrile/water. A standard working solution was
207 prepared by mixing appropriate volumes of each stock solution to reach the final concentration of
208 2.0 – 50.0 $\mu\text{g mL}^{-1}$ in acetonitrile/water (1:1, %/v).

209

210 **Sample preparation**

211 A total of 30 μL of plasma (in duplicate) were mixed with the same volume of the IS mixture and
212 500 μL of a degassed mixture of pre-chilled acetonitrile/isopropanol/water (3:3:2, v/v/v). After
213 vortexing for 20 s and incubating in ice in ultrasonic water bath for 5 min, samples were
214 centrifuged at $12,000 \times g$ at 4°C for 5 min and the supernatant (480 μL) was dried under Nitrogen
215 gas. Samples were reconstituted with 60 μL of acetonitrile/water (1:1, v/v) containing $2 \mu\text{g mL}^{-1}$
216 of the IS *p*-fluoro-L-phenylalanine, vortexed for 15 s, and centrifuged as above. The resulting
217 supernatant was used for LC-MS analysis.

218 A pooled quality control (QC) sample was prepared combining 5 μL of each plasma before
219 extraction and processed in the same way as the specimen samples. QC samples were injected
220 every 10th biological sample to monitor the stability of the analytical system as well as the
221 reproducibility of the procedure for sample treatment [36].

222 Subgroups of pooled QC samples (control, survivors, or non-survivors) were created to collect
223 fragmentation spectra via data-dependent acquisition (DDA) mode on the mass spectrometer. The
224 analysts running MS-based experiments were blinded on the sample grouping until the end of data
225 analysis to limit biased peak annotation.

226 **LC-MS conditions**

227 Liquid chromatography (LC) analysis was performed on a Dionex UltiMate 3000 UHPLC
228 (Thermo Fisher Scientific, Bremen, Germany) system using a Waters[®] ACQUITY UPLC[®] BEH
229 amide column (150 x 2.1 mm x 1.7 μm) by gradient elution at a constant flow rate of $350 \mu\text{L min}^{-1}$.
230 The column oven temperature and injection volume were set to 40°C and 5.0 μL , respectively.

231 Two different mobile phase compositions, with different pH values, were used. One consisted of
232 (A) water:acetonitrile (95:5, v/v) and (B) acetonitrile:water (95:5, v/v) both with 0.1 % formic acid
233 (pH 3) and the other consisted of (A) water:acetonitrile (95:5, v/v) and (B) acetonitrile:water (95:5,
234 v/v) both with 0.05 % ammonium hydroxide and 10 mM ammonium acetate (pH 8). The gradient
235 elution was 0-0.5 min 100 % B; 0.5-5.0 min 45 % B; 5.0-9.0 min 45 % B; 9.0-10.0 min 100 % B;
236 10.0-15.0 min 100 % B.

237 The LC was coupled to a hybrid Quadrupole-Orbitrap high resolution and accurate mass
238 spectrometer (QExactive Plus, Thermo Scientific) equipped with a heated electrospray ion source
239 operating in both negative (ESI-) and positive (ESI+) ionization modes. Source ionization
240 parameters were: spray voltage -3.6 kV/+3.9 kV; capillary temperature 270°C; probe heater
241 temperature 380°C; S-Lens RF level 50, sheath and auxiliary gases 50 and 10 (arbitrary units),
242 respectively. Samples were analyzed in Full MS mode in the scan range of m/z 50-710 at the
243 resolution of 70,000 FWHM (full width at half maximum). The automatic gain control (AGC)
244 target was set at 1.0e6 with a maximum injection time (IT) of 150 ms.

245 The solution of target analytes and the subgroups pooled QC samples were analyzed in Full MS
246 followed by data-dependent acquisition (dd-MS² top5 experiment) in the same scan range as
247 above. For the full MS scan, the mass resolution was set to 17,500 FWHM with the following
248 settings: AGC target 1.0e6 and maximum IT of 80 ms. For the dd-MS² scan, the mass resolution
249 was set to 17,500 FWHM with following settings: AGC target at 1.0e5, maximum IT of 50 ms,
250 isolation window at m/z 1.2, normalized collision energy (NCE) 15, 35 (ESI+) and 10, 30 (ESI-),
251 intensity threshold at 1.0e6, exclude isotopes "on", and dynamic exclusion of 10.0 s.

252

253 **Non-targeted and targeted LC-HRMS-based metabolomics**

254 For the non-targeted analysis, the LC-HRMS data files were submitted to a metabolomics
255 workflow using MS-DIAL software (RIKEN, version 4.80) [37] for data processing, including
256 peak matching against an MS/MS library. The parameters used for both pH 8 and pH 3 analyses
257 are described in Supplementary table 3. Features were selected assuming coefficient variation
258 (CV) % values less than 30 % in QC samples and Gaussian-like peak shape according to the
259 protocols for quality control used in untargeted metabolomics [36, 38].

260 Compound annotation was done i) based on the MS/MS fragment comparison with the standard
261 compounds, ii) by comparing the aligned m/z ions with a mass error below 6 ppm to those available
262 at the HMDB [34] and METLIN website, and iii) by comparing the investigated MS/MS spectra
263 with a similarity score $\geq 80\%$ to those in the NIST 20 Tandem Mass Spectral Library and
264 MassBank of North America using a customized MSP file in MS-DIAL. Furthermore, molecular
265 formulas were determined using MS-FINDER (RIKEN, version 3.52) [39].

266 Targeted data analysis was performed as a confirmation step for the non-targeted approach, in
267 TraceFinder software v3.1 (ThermoFisher Scientific, Waltham, Massachusetts, EUA). An in-
268 house library that includes retention time, exact mass and fragments of the target compounds was
269 used. As identification criteria, mass errors less than 5 ppm and retention time variation of $<1\%$
270 compared to the defined retention time were accepted [40]. Supplementary Tables 1 and 2 present
271 the target compounds monitored via the method at pH 8 and pH 3, respectively.

272

273

274 **Statistical Analysis**

275 Sample size was determined by the feasibility of recruitment and eligibility criteria.

276 Data distribution was analyzed using the Shapiro-Wilk test and median and interquartile intervals,

277 and the Mann–Whitney or Kruskal-Wallis tests were used for data with asymmetrical distribution.

278 Categorical variables were compared using the Fisher’s exact test with absolute (n) and relative

279 (%) frequencies.

280 Data derived from processed NMR spectra was subjected to the multivariate statistics Principal

281 Component Analysis using the MetaboAnalyst 4.0 [41] platform. For the univariate statistics,

282 Kruskal-Wallis and Dunn’s post-hoc tests were used for variables’ comparison of non-transformed

283 NMR or MS data. Interaction between sex and disease was analyzed using two-way ANOVA and

284 Tukey’s multiple comparison tests. GraphPad Prism version 8.4.3 was used for all analysis. $P <$

285 0.05 was considered for rejection of the null hypothesis.

286 Classification and regression tree (CART) models [42] were fitted to assess which metabolites best

287 predict the observed morbidity class of study participants. The model fitting algorithms have been

288 implemented in library "rpart" [43] for the R programming language. We set “method = “class”

289 and the remaining parameters were kept at the default values for all models. For CART models,

290 the results of NMR-based metabolomics were used, in addition to the subjects’ sex and age.

291

292

293 **Results**

294 **Subjects' demographics and clinical parameters**

295 A total of 47 plasma samples were included in this study; 12 samples were from non-infected
296 control subjects and 35 samples from individuals with severe cases of COVID-19, grouped into
297 survivors (n= 18) and non-survivors (n= 17), according to the 28-day mortality outcome. The
298 demographics and clinical characteristics of all subjects included in the study are shown in Table
299 1. Briefly, age, sex distribution and co-morbidities were similar among groups. The non-invasive
300 oxygen supplementation was used in 44 % of subjects in the survivors group whereas 100 % of
301 the subjects in the non-survivors group received mechanical ventilation.

302 Laboratory findings revealed that patients in the survivors group presented ~ 50 % more monocyte
303 counts ($p=0.009$) if compared to non-survivors. At admission in the ICU, leukocytes and platelet
304 counts were similar between the two groups of infected patients.

306 **Table 1: Demographics and clinical characteristics of control, COVID-19 survivors and non-**
 307 **survivors.**

	control (n=12)	survivors (n=18)	non-survivors (n=17)	P value
Age, years	50 (36–59)	56 (39–63)	58 (51–73)	0.344
Sex, male; <i>n</i> (%)	5 (41 %)	7 (38 %)	10 (58 %)	0.727
Respiratory support; <i>n</i> (%)				
Noninvasive O ₂ supplementation	0 (0 %)	8 (44 %)	0 (0 %)	0.003
Mechanical ventilation	0 (0 %)	10 (66 %)	17 (100 %)	
SAPS II	n.a.	55 (37–64)	68 (59 – 78.5)	0.001
PaO ₂ /FiO ₂ ratio	n.a.	196 (154–429)	139 (177–178)	0.099
Time from symptom onset to blood sample (days)	n.a.	10 (7–14)	10 (3– 14)	0.975
Comorbidities; <i>n</i> (%)				
Obesity	1 (8.3 %)	5 (27.7 %)	2 (11.7 %)	0.650
Hypertension	2 (16%)	4 (22%)	5 (29 %)	0.855
Diabetes	0 (0 %)	6 (33 %)	6 (35 %)	0.990
Cancer	0 (0 %)	2 (11 %)	2 (11 %)	0.990
Heart disease ¹	0 (0 %)	2 (11 %)	2 (11 %)	0.990
Laboratory findings at admission				
Leukocytes, x 1000/μL	n.a.	12.4 (9.1–14.5)	14.8 (11.5–21.7)	0.097
Lymphocytes, cells/μL	n.a.	1,288 (939–1.579)	1,035 (284–1.706)	0.521
Monocytes, cells/μL	n.a.	495 (448–742)	738 (599–1.005)	0.009
Platelet count, x 1000/μL	n.a.	198 (154–324)	187 (131–240)	0.125

308 Continuous variables are represented as median and interquartile range. Categorical variables are
 309 represented as *n* (frequency %).

310 n.a. – not applicable

311 ¹Coronary artery disease or congestive heart failure.

312 Categorical variables were compared using the two tailed Fisher exact test, and the continuous
 313 variables using Student’s *t* or ANOVA tests for parametric and the Mann Whitney U or Kruskal-
 314 Wallis tests for nonparametric distributions. Significant p values are in bold.

315

316

317

318 ¹H NMR- and MS-based metabolomics

319 Representative spectra of aliphatic (Figs 1A and 1B), amidic and aromatic (Fig 1C) regions
320 indicate important differences in the metabolite profile among the three groups. Discriminating
321 metabolites as (CH₃)₃ choline-related metabolites, creatine/creatinine, amino acids, organic acids,
322 and broad residual signals of lipids are depicted followed by arrows indicating higher/lower
323 contents in severe COVID-19 cases. A discriminating metabolite profile was confirmed with
324 Principal Component Analysis (PCA) scores plot (Fig 1D) where principal components 1, 2, and
325 3 accounted for approximately 70 % of the variation among groups. PCA loading factors plot
326 highlights (CH₃)₃ choline, creatine/creatinine, lactate, acetate, and broad signals of CH₃ and CH₂
327 lipoproteins as discriminating variables (Supplementary Fig 1).

328
329 **Figure 1. ¹H NMR-based metabolomics shows different plasma metabolite profiling in severe COVID-19 patients compared**
330 **to control subjects.** ¹H NMR representative spectra of control (red), COVID-19 survivors (green) and non-survivors (blue).
331 Metabolites that differ significantly among groups are indicated as higher (↑) or lower (↓) contents compared to controls; (A) and
332 (B) aliphatic region (3 × magnified); (C) amidic and aromatic regions (21 × magnified); (D) Principal Component Analysis 3D
333 scores plot shows discriminating profiling among groups.

334
335 To gain meaningful insight into the changes associated with disease severity and outcome,
336 metabolites that exhibited significant differences in content among groups, according to the PCA
337 results, were selected. NMR-based metabolomics revealed that the levels of (CH₃)₃-choline
338 metabolites, including glycerophosphocholine, phosphocholine, and choline, as well as glycine,
339 which is associated with one-carbon metabolism, were significantly lower in both survivors and
340 non-survivors, if compared to controls (Figs 2A and 2B). Additionally, ¹H NMR-based
341 metabolomics identified several metabolites related to glucose, insulin sensitivity, and
342 inflammation that were significantly higher in infected subjects (Figs 2C-G), including

343 creatine/creatinine (considered together due to signal overlap), *N*-acetyl ¹H of glycoproteins, and
344 lactate. Importantly, creatine/creatinine set apart non-survivors from survivors and control
345 subjects, as the levels were higher in the former. Lower levels of acetate and higher levels of
346 formate, a byproduct of bacteria metabolism in the gut, were observed in infected subjects but not
347 in controls (Figs 2F and G). Additionally, residual signals of (CH₂) of VLDL-lipoproteins, lipids
348 (CH=CH olefinic protons of triacylglycerols) and acetoacetate, a ketone body, were significantly
349 higher in both groups of infected subjects if compared to controls (Figs 2H-J).

350 ¹H NMR-metabolomics findings also suggest that the dysregulation in amino acid metabolism is
351 a function of severe COVID-19, as survivors and non-survivors had plasma levels of glutamine,
352 alanine, branched-chain amino acids (valine, leucine, isoleucine) and tyrosine lower than those
353 observed in controls (Figs 2K-P). Supplementary Tables 4 and 5 present the ¹H NMR assignment
354 information for the metabolites and broad signals of lipids and proteins that distinguished the
355 groups, in both PCA and univariate analysis.

356

357 **Figure 2. Metabolites that were significantly altered in severe COVID-19, according to ¹H NMR-based metabolomics.** Most
358 discriminating metabolites according to PCA loading factors, presenting significant differences among groups. Control, n= 12 (red
359 circles); Survivors, n=18 (green circles); Non-survivors, n=17 (blue circles). Metabolites related to one-carbon metabolism (A,B):
360 (CH₃)₃ choline-related metabolites and glycine; metabolites related to glucose metabolism, insulin sensitivity and inflammation
361 (C-G): creatine/creatinine, *N*-Acetyl of glycoproteins, lactate, acetate and formate; metabolites related to lipid metabolism (H-J):
362 CH₂ lipoproteins (mainly VLDL), lipids-TAG (CH=CH olefinic protons of triacylglycerols) and acetoacetate; metabolites related
363 to amino acids and protein metabolism (K-P): glutamine, alanine, valine, isoleucine, leucine, tyrosine; metabolites' contents were
364 determined according to their respective peak intensity. Data were presented as median with interquartile range and only significant
365 *P* values are shown, according to Kruskal-Wallis and Dunn's post-hoc tests.

366

367 To further investigate the changes in plasma metabolome associated with severe COVID-19, LC-
368 high-resolution mass spectrometry (LC-HRMS)-based metabolomics was used. In the current
369 study, LC-HRMS allowed us to confirm the alterations detected by the ¹H NMR-based

370 metabolomics in amino acids and protein metabolism and in ketogenesis. Importantly, it allowed
371 us to discriminate the metabolic abnormalities associated with fatal COVID-19 and to complement
372 the NMR data, providing insightful information regarding the alterations in one-carbon
373 metabolism and in metabolites associated with insulin sensitivity and inflammation. Metabolites
374 related to one-carbon metabolism glycerophosphocholine, serine, betaine, and histidine were
375 lower (Figs 3A-D) whereas xanthine and hypoxanthine were higher in infected subjects, if
376 compared to controls (Figs 3E and 3F). The lower levels of glycerophosphocholine in the survivors
377 and non-survivors groups, when compared to control subjects, support the ¹H NMR-based
378 metabolomics results, which detected lower (CH₃)₃ choline-related metabolites in the two groups
379 of infected patients. Metabolites associated with inflammation were significantly higher in infected
380 subjects, if compared to controls. Importantly, creatinine, 4-hydroxyproline, gluconic acid and *N*-
381 acetylserine were significantly higher in the non-survivors group, when compared to both
382 survivors and control groups (Figs 3G-J). The higher levels of creatinine in non-survivors
383 confirmed the results of the NMR analysis (Fig 2C). Moreover, asymmetric dimethylarginine and
384 methylmalonic acid were significantly higher in survivors and non-survivors, when compared to
385 control subjects (Figs 3K and 3L). MS-based metabolomics revealed significantly higher content
386 of β-hydroxybutyrate – a ketone body (Fig 3M) and lower content of the amino acid tryptophan
387 (Fig 3N) in infected subjects, if compared to controls. Supplementary Fig 2 shows the essential
388 stability of the QC samples throughout the run, which was within SD limit. Additionally, the IS *p*-
389 fluoro-DL-phenylalanine and U-¹³C D-glucose, which were added to all samples, showed that the
390 CV was less than 10 %, indicating that the differences observed in metabolites among groups could
391 be attributed to biological variation and not to the variability of the analytical system.
392 Supplementary Tables 6 and 7 show the parameters of the assigned metabolites with significant

393 differences among groups according to the non-targeted MS-metabolomics in the negative and
394 positive modes, respectively.

395
396 **Figure 3. High-resolution mass spectrometry-based metabolomics shows altered plasma metabolic profile in severe COVID-**
397 **19.** Assigned metabolites in the untargeted and confirmed in the targeted approach, presenting significant differences among
398 groups. Control, n=12 (red circles); Survivors, n=18 (green circles); Non-survivors, n=17 (blue circles). Metabolites related to one-
399 carbon metabolism (A-D): glycerophosphocholine, serine, betaine, histidine and to nucleic acid metabolism (E-F): xanthine,
400 hypoxanthine; metabolites related to glucose metabolism, insulin sensitivity and inflammation (G-L): creatinine, 4-hydroxyproline,
401 asymmetric dimethylarginine, gluconic acid, N-acetyl serine, methylmalonic acid. Metabolite related to lipid metabolism (M): β -
402 hydroxybutyrate; metabolite related to amino acid metabolism (N): tryptophan. Metabolites' contents were determined according
403 to their respective peak intensity. Data were presented as median with interquartile range and only significant *P* values are shown,
404 according to Kruskal-Wallis and Dunn's post-hoc tests.

405
406 CART models were built to assess the predictive power of metabolites levels in classifying study
407 participants into control, survivors and non-survivors. This model was built using the data from
408 the NMR-metabolomics and considered only the metabolites that showed discriminatory power
409 among the groups identified by the multivariate PCA analysis (Fig 2). Additionally, the subjects'
410 sex and age were included in the model. Supplementary Figure 3 shows a CART model fitted to
411 data indicating that choline-related metabolites had the highest predictive power with a first
412 partition point at 2.064. The classification tree shows that over 92 % of control subjects followed
413 the classification of ≥ 2.064 , and most survivors (95 %) and non-survivors (89%) were classified
414 as < 2.064 . In addition to the first partition point at choline-related metabolites, we also observed
415 a second partition criteria at creatine/creatinine < 1.473 . For this second partition, most survivors
416 were included (~70 %). Conversely, for the non-survivors, the majority were classified at ≥ 1.473
417 (64 %). Supplementary Fig 3 presents the final allocation contingent among the morbidity classes
418 achieved by applying the two classification criteria. These results clearly suggest that choline-
419 related metabolites have a protective effect. As opposed to creatine/creatinine, where higher
420 contents predicted fatal outcomes.

421 **Lipoproteins dynamics**

422 A complete characterization of lipoproteins was performed (Fig 4) and significant changes were
423 observed as a function of severe COVID-19. The results show that survivors and non-survivors
424 presented lower concentrations of total cholesterol, LDL, and HDL, if compared to controls (Figs
425 4A-C). VLDL and triacylglycerol concentrations were significantly higher (Figs 4D-E) and non-
426 HDL cholesterol (Fig 4E) was significantly lower in the non-survivors, if compared to controls.

427
428 **Figure 4. Lipoprotein dynamics changed significantly in severe COVID-19.** (A) Total Cholesterol, (B) Low Density
429 Lipoprotein - LDL, (C) High Density Lipoprotein - HDL, (D) Very Low-Density Protein - VLDL, (E) Triacylglycerol, (F) non-
430 HDL cholesterol, (G) Cholesterol-to-HDL ratio and (H) LDL-to-HDL ratio. Control, n= 12 (red circle); Survivors, n=18 (green
431 circle); Non-survivors, n=17 (blue circle). Data were presented as median with interquartile range and only significant *P* values are
432 shown, according to Kruskal-Wallis and Dunn's post-hoc tests.

433

434 **Sex-based differences in lipoproteins and metabolites**

435 Lastly, we investigated whether changes in lipoproteins and in metabolites associated with severe
436 COVID-19 differed according to sex, by two-factor analysis (Fig 5). In general, the changes
437 observed in female subjects mirrored the changes described above, when considering all subjects.
438 Our findings indicate that the strongest effect was seen in severe COVID-19 cases and no
439 differences between men and women within group were observed. However, for HDL, total
440 cholesterol, non-HDL cholesterol, LDL to HDL and HDL to cholesterol ratios, significant
441 interactions between disease and sex were observed. Additionally, lower contents of HDL (Fig
442 5C) and higher contents of VLDL (Fig 5D) and triacylglycerols (Fig 5E) were observed in female
443 but not in male subjects in the non-survivors group, when compared to controls.

444 The same sex-related pattern changes were observed for selected metabolites analyzed by ^1H
445 NMR-based metabolomics, where the strongest effect was seen in severe COVID-19 cases (Figs
446 5I-L). Lower content of $(\text{CH}_3)_3$ choline-related metabolites (Fig 5I) and higher content of *N*-acetyl
447 of glycoproteins (Fig 5K) were observed among females in both survivors and non-survivors, if
448 compared to controls, whereas among men these differences were observed only between
449 survivors and controls. Additionally, higher contents of acetoacetate (Fig 5J) and
450 creatine/creatinine (Fig 5L), as a function of severe COVID-19, were only observed in women but
451 not in men. Indeed, for acetoacetate and creatine/creatinine, significant interactions between
452 disease and sex were observed. There were no significant differences in amino acids and one-
453 carbon metabolism-related compounds when sex was considered as a variable.

454 The metabolic alterations observed in severe COVID-19 are shown in Fig 6.

455
456 **Figure 5. Severe COVID-19 induced changes in lipoproteins and metabolites that are greater in women than in men.** (A)
457 Total Cholesterol, (B) Low Density Lipoprotein - LDL, (C) High Density Lipoprotein - HDL, (D) Very Low-Density Protein -
458 VLDL, (E) Triacylglycerol, (F) non-HDL cholesterol, (G) Cholesterol-to-HDL ratio and (H) LDL-to-HDL ratio, (I) $(\text{CH}_3)_3$ Choline,
459 (J) Acetoacetate, (K) *N*-acetyl of glycoprotein, (L) Creatine/creatinine. Female subjects: control, n=7 (red triangles); survivors,
460 n=11 (green triangles); non-survivors, n=7 (blue triangles). Male subjects: control, n= 5 (red squares); survivors, n=7 (green
461 squares); non-survivors, n=10 (blue squares). Data were presented as median with interquartile range and *P* values are shown,
462 according to two-factor ANOVA and Tukey's multiple comparison tests.

463
464 **Figure 6. Metabolic alterations in severe COVID-19.** Summary of changes in plasma metabolites in survivors and non-survivors
465 subjects. Metabolites that differ significantly among groups are indicated as higher (\uparrow) or lower (\downarrow) contents compared to controls.
466 Metabolites in bold were higher in the fatal cases of the disease compared to survivors and controls. * indicates metabolites with
467 changes greater in women than in men. This figure was created with BioRender.com.

468
469
470

471 **Discussion**

472 The present study aimed to investigate plasma metabolic changes in samples from survivors and
473 non-survivors of severe COVID-19 infection. Our goal was to search for potential metabolic
474 pathways that could be involved in COVID-19 pathophysiology and disease outcome. We
475 identified significant changes in a plethora of metabolites, indicating that severe COVID-19
476 dysregulates one-carbon, lipid, and amino acid metabolism and lipoprotein dynamics.

477 Higher contents of creatine/creatinine, 4-hydroxyproline, gluconic acid and *N*-acetylserine in non-
478 survivors, if compared with survivors and control groups, indicate that these metabolites are
479 associated with uncontrolled inflammation, multi-organ dysfunction, particularly liver and
480 kidneys, and some degree of insulin resistance in fatal COVID-19. They may be considered as
481 biomarkers for prognostic purposes and to monitor how different organs and tissues respond to the
482 infection. For instance, gluconic acid has been previously linked to hyperglycemia and brain injury
483 in ischemic stroke [44], and it may be considered a marker of oxidative stress. Additionally, *N*-
484 acetylation of amino acids, including the formation of *N*-acetylserine, has been associated with
485 SARS-CoV-2 infection and COVID-19 pathogenesis [45] whereas higher levels of *N*-acetylserine
486 have been recently considered a marker of progression of chronic kidney disease [46].

487 Higher plasma contents of creatine/creatinine can be an indication of lower sensitivity to insulin,
488 as we observed in the fatal cases of COVID-19. Although higher creatine levels in severe COVID-
489 19 have been associated with kidney dysfunction [26], and are important for viral replication [47],
490 recent findings place creatine as a key metabolite involved in the regulation of adipocyte
491 thermogenesis and whole-body energy metabolism and immunity [48,49]. Therefore, higher levels

492 of creatine/creatinine in infected subjects can be regarded as a biomarker of detrimental effects on
493 metabolic health and immune responses imposed by SARS-CoV-2 infection.

494 Higher levels of 4-hydroxyproline found in non-survivors is a strong indication of disturbed amino
495 acid metabolism induced by SARS-CoV-2 infection, as already suggested [20, 23-25]. In humans,
496 4-hydroxyproline in blood is a product of protein degradation, mainly collagen. Most 4-
497 hydroxyproline is recycled back to synthesize glycine by the liver and kidneys and this seems to
498 be an important source of glycine for cells and tissues [50]. Therefore, the significantly higher
499 levels of 4-hydroxyproline in non-survivors can be regarded as a feature of severe COVID-19,
500 suggestive of liver dysfunction and lower availability of glycine. This result reveals a potential
501 disruption in the one-carbon metabolism pathway, which is significant as glycine serves as a
502 crucial methyl donor in this pathway. This disruption has already been described previously [27].
503 In addition to glycine, significant lower contents of serine, betaine and histidine, which are
504 metabolites also involved in the one-carbon metabolism, were found in infected subjects.
505 Importantly, the significant drop in choline-related metabolites (as observed in the NMR-based
506 metabolomics) which agrees with a drop in glycerophosphocholine (by MS-based metabolomics),
507 strengthens the idea that severe COVID-19 alters one-carbon metabolism and affects the availability
508 of methyl donors. Indeed, a comprehensive characterization of the alterations in one-carbon
509 metabolism would help integrating the metabolic changes in glucose, amino acid, nucleotide, and
510 lipid metabolism [51], as well as provide us with a better understanding of the alterations in
511 epigenetic regulation and redox homeostasis associated with severe COVID-19.

512 Phosphatidylcholine is the most abundant phospholipid and in humans its synthesis is probably
513 the main point of deviation for one-carbon donors [52]. Our results show that severe COVID-19
514 alters lipoprotein dynamics, as indicated by lower contents of total cholesterol and HDL- and LDL-

515 cholesterol and higher contents of VLDL and triacylglycerols, particularly in fatal COVID-19 (Fig
516 4). Therefore, one may speculate that the alterations in one-carbon metabolism observed in
517 infected subjects caused the drop in choline-related metabolites which significantly disrupted
518 lipoproteins dynamics, as indicated by other studies [52,53]. Conversely, lower choline availability
519 may have contributed to reduced phospholipid synthesis by the liver and disturbed lipoproteins
520 dynamics, as choline deficiency is known to alter lipid metabolism and to induce liver fibrosis
521 [53]. Another indication of the effect of SARS-CoV-2 infection on host lipid metabolism and
522 lipoproteins dynamics was recently shown by our group, where simvastatin, by disrupting lipid
523 rafts in human epithelial lung cells, prevented SARS-CoV-2 entry and replication [54].
524 Importantly, NMR-based metabolomics has also shown that alterations in lipoprotein dynamics
525 may be associated with systemic effects of COVID-19, even in subjects in the recovery phase of
526 the disease. Particularly, the HDL subfraction negatively correlates with inflammatory cytokines
527 [55]. Additionally, apolipoproteins alterations are more pronounced in the fatal cases of COVID-
528 19 [56].

529 This scenario is compatible with the CART model fitted to data (Supplementary Fig 3), which
530 indicates that choline-related metabolites had the highest predictive power with a first partition
531 point at 2.064, demonstrating that most survivors (95 %) and non-survivors (89%) were classified
532 as < 2.064 ; and that higher content of creatine/creatinine is a strong predictor of disease fatality.
533 Recent evidence links choline metabolism in the liver and the gut microbiota to endothelial
534 function and thrombosis [57,58], which is one of the clinical manifestations associated with disease
535 progression and severe COVID-19 [59]. Indeed, choline seems to be essential to sustain
536 mitochondrial energetics and maximal platelet activation, and, therefore, to regulate thrombosis
537 [60].

538 We also found increased levels of asymmetric dimethylarginine in infected subjects, which is
539 produced by arginine methylation. Therefore, asymmetric dimethylarginine synthesis is directly
540 related to one-carbon metabolism for methyl donor availability. Additionally, asymmetric
541 dimethylarginine has been strongly associated with fibrosis in the liver, kidney, and heart [61,62],
542 tissues that are compromised in COVID-19. Therefore, these data strongly support that alterations
543 in one-carbon and amino acid metabolism are linked to liver damage in most severe outcomes of
544 COVID-19.

545 Our study confirmed that severe COVID-19 induced important changes in amino acid metabolism,
546 where significantly lower contents of alanine, BCAA (valine, isoleucine, leucine), glutamine,
547 tryptophan, glycine, and tyrosine were found in both survivors and non-survivors, if compared to
548 control subjects. Lower amino acid levels may indicate an increase in amino acid catabolism to
549 provide the necessary supply of carbons and ATP to support viral replication [16, 63, 64]. For
550 instance, isoleucine [65] and glutamine [66] seem to be essential for SARS-CoV-2 replication. In
551 the case of glutamine, it has been shown that inhibition of glutaminolysis halted SARS-CoV-2 in
552 primary astrocytes in a rodent model; authors suggested that lower availability of glutamine is a
553 contributing factor for the neurological impairments observed in long post-COVID. Additionally,
554 a decrease in plasma glutamine [67] and lower salivary levels of tyrosine and BCAA [68] seem to
555 be associated with COVID-19 severity, which supports our findings.

556 Lower levels of glutamine in the plasma may indicate an increased use of this amino acid,
557 especially by the host's liver and immune cells. This increased use may be needed to support the
558 synthesis of proteins and inflammatory mediators during the acute phase of infection. Indeed, the
559 liver is actively involved in the synthesis of acute-phase proteins. In this context, the assigned
560 broad signals of *N*-Acetyl of glycoproteins, which were higher in severe COVID-19 subjects (Fig

561 2D), may include signals from the acute-phase proteins, such as α_1 -acid glycoprotein, α_1 -
562 antitrypsin, and haptoglobin and to the ^1H from sidechains of N-acetyl-glucosamine and N-
563 acetylneuraminic acid [69]. ^1H signals of N-acetyl of glycoproteins have been suggested to be
564 markers of SARS-CoV-2 infection and inflammation and to be implicated in long post-COVID
565 symptoms as well [70]. Indeed, enrichment analysis of genes associated with cases of severe
566 COVID-19 indicates acute phase response and inflammation among the most significant biological
567 functions altered, accordingly to a recently multi-omic analysis of COVID-19 datasets [71].

568 Other authors have shown that liver infection by SARS-CoV-2 directly contributes to hepatic
569 dysfunction and that deceased subjects often presented abnormal liver enzymes, microvesicular
570 steatosis and mild inflammatory infiltrates in the hepatic lobule and portal tract [72,73]. The
571 increase in purine metabolites (xanthine and hypoxanthine) may also be regarded as a direct effect
572 of SARS-CoV-2 infection in the liver that enables virus replication. Higher levels of
573 deoxycytidine, associated with increased viral load, have already been associated with severe and
574 fatal outcomes [74]. Accordingly, the liver of patients with severe COVID-19 shares many
575 similarities with the non-alcoholic fatty liver disease (NAFLD), a common manifestation of the
576 metabolic syndrome that can progress to hepatocyte injury, inflammation, and fibrosis [75,76].

577 Lastly, the higher levels of acetoacetate and β -hydroxybutyric acid observed in infected subjects
578 also reflect the impact of severe COVID-19 on liver function. Dysregulation in ketogenesis is also
579 associated with the pathogenesis of NAFLD and decreased insulin sensitivity, an important
580 manifestation of metabolic syndrome. In this scenario, enhanced ketogenesis seems to be a
581 consequence of increased influx and accumulation of lipids in the liver (e.g., triacylglycerols),
582 which in turn results in an increased flux of Acetyl-CoA [77].

583 This is the first study to demonstrate host metabolic disturbances associated with severe COVID-
584 19 and to investigate the responses in the fatal cases of the disease in hospitalized subjects in Rio
585 de Janeiro, during the early months of the COVID-19 pandemic in Brazil. Whilst our study
586 provides new insights into the metabolic disturbances associated with fatal outcomes of COVID-
587 19, one limitation is its reduced sample size. Nonetheless, since the incidence of severe outcomes
588 after hospital discharge can be very high in Brazil [73], these metabolic alterations may be
589 considered to improve our understanding of the pathophysiology of long-post COVID.

590 Our results show that alterations in key metabolites, such as choline-metabolites,
591 creatinine/creatinine, ¹H signals of N-acetyl of glycoproteins, and acetoacetate, as well as changes
592 in lipoproteins are greater in women. Even though current evidence indicates that men are more
593 vulnerable to severe COVID-19 and higher mortality rates have been observed in this category
594 [78], women seem to be more susceptible to developing long COVID syndrome [79]. Our study
595 highlights the importance of considering the sex-based differences here described, when
596 monitoring and treating COVID-19 patients. These differences should also be considered when
597 designing strategies for pandemic surveillance. Doing so may lead to better disease stratification
598 and improved patient outcomes.

599

600 **Acknowledgments**

601 The authors acknowledge the contribution of the subjects who participated in this study, without
602 receiving any direct compensation.

603

604 References

- 605 1. Cohen LE, Spiro DJ, Viboud C. Projecting the SARS-CoV-2 transition from pandemicity to
606 endemicity: Epidemiological and immunological considerations. *PLoS Pathog.* 2022;
607 30;18(6):e1010591. doi: 10.1371/journal.ppat.1010591.
608
- 609 2. WHO. COVID-19 Weekly Epidemiological Update 35. World Health Organization. 2021
610 Dec:1–3.
611
- 612 3. Brasil. Secretarias Estaduais de Saúde. Painel Coronavirus. 2023. Available from:
613 <https://covid.saude.gov.br/2023>
614
- 615 4. Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections:
616 Epidemiological, clinical and immunological features and hypotheses. *Cell Stress.* 2020, 4: 66–
617 75. doi: 10.15698/cst2020.04.216
618
- 619 5. Xiao N, Nie M, Pang H, Wang B, Hu J, Meng, X. et al. Integrated cytokine and metabolite
620 analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic
621 implications. *Nat Commun.* 2021; 12: 1618. doi: 10.1038/s41467-021-21907-9
622
- 623 6. WHO. Coronavirus disease (COVID-19): Post COVID-19 condition. World Health
624 Organization. 2021. Available from: [https://www.who.int/news-room/questions-and-](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition)
625 [answers/item/coronavirus-disease-\(covid-19\)-post-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition)
626
- 627 7. Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group.
628 Persistent Symptoms in Patients After Acute COVID-19. *JAMA.* 2020, 324: 603–605. doi:
629 10.1001/jama.2020.12603.
630
- 631 8 Fernández-de-Las-Peñas C, Rodríguez-Jiménez J, Cancela-Cilleruelo I, Guerrero-Peral A,
632 Martín-Guerrero JD, García-Azorín D, et al. Post-COVID-19 Symptoms 2 Years After SARS-
633 CoV-2 Infection Among Hospitalized vs Nonhospitalized Patients. *JAMA Netw Open.* 2022;
634 5(11):e2242106. doi: 10.1001/jamanetworkopen.2022.42106.]
635
- 636 9. dos Santos GC, Renovato-Martins M, de Brito NM. The remodel of the “central dogma”: a
637 metabolomics interaction perspective. *Metabolomics.* 2021; 17 (5):48. doi: 10.1007/s11306-021-
638 01800-8.
639
- 640 10. Byers NM, Fleshman AC, Perera R, Molins CR. Metabolomic insights into human arboviral
641 infections: Dengue, chikungunya, and zika viruses. *Viruses.* 2019; 11 (3): 225.
642 doi:10.3390/v11030225
643
- 644 11. El-Bacha T, Struchiner CJ, Cordeiro MT, Almeida FCL, Marques ET, Da Poian AT. ¹H
645 Nuclear Magnetic Resonance Metabolomics of Plasma Unveils Liver Dysfunction in Dengue
646 Patients. *J Virol.* 2016; 90(16): 7429–7443. doi: 10.1128/JVI.00187-16
647

- 648 12. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered Lipid Metabolism in Recovered
649 SARS Patients Twelve Years after Infection. *Sci Rep.* 2017; 7(1):9110. doi: 10.1038/s41598-017-
650 09536-z.
- 651
- 652 13. Melo CFOR, Delafiori J, de Oliveira DN, Guerreiro TM, Esteves CZ, Lima E de O. et al.
653 Serum metabolic alterations upon ZIKA infection. *Front Microbiol.* 2017; 8: 1954. doi:
654 10.3389/fmicb.2017.01954
- 655
- 656 14. Diop F, Vial T, Ferraris P, Wichit S, Bengue M, Hamel R, et al. Zika virus infection modulates
657 the metabolomic profile of microglial cells. *PLoS One.* 2018; 13: e0206093.
658 doi.org/10.1371/journal.pone.0206093
- 659
- 660 15. Girdhar K, Powis A, Raisingani A, Chrudinová M, Huang R, Tran T, et al. Viruses and
661 Metabolism: The Effects of Viral Infections and Viral Insulins on Host Metabolism. *Annu Rev*
662 *Virol.* 2021; 8(1): 373–391. doi: 10.1146/annurev-virology-091919-102416.
- 663
- 664 16. El-Bacha, T.; Da Poian, A.T. Virus-induced changes in mitochondrial bioenergetics as
665 potential targets for therapy. *Int J Biochem Cell Biol.* 2013; 45 (1): 41–46. doi:
666 10.1016/j.biocel.2012.09.021. Epub 2012 Oct 2.
- 667
- 668 17. Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, Laugks U, Zheng S, de Jong AWM. et al.
669 A molecular pore spans the double membrane of the coronavirus replication organelle. *Science.*
670 2020; 369 (6509): 1395–1398. doi: 10.1126/science.abd3629.
- 671
- 672 18. Dias SSG, Soares VC, Ferreira AC, Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR,
673 et al. Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators.
674 *PLoS Pathog.* 2020; 16 (12): e1009127. doi: 10.1371/journal.ppat.1009127
- 675
- 676 19. Ricciardi S, Guarino AM, Giaquinto L, Polishchuk EV, Santoro M, Di Tullio G, et al. The role
677 of NSP6 in the biogenesis of the SARS-CoV-2 replication organelle. *Nature.* 2022; 606: 761-768.
678 Doi:10.1038/s41586-022-04835-6.
- 679
- 680 20. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic
681 Characterization of COVID-19 Patient Sera. *Cell.* 2020; 182 (1): 59-72.e15. doi:
682 10.1016/j.cell.2020.05.032
- 683
- 684 21. Rössler T, Berezhnoy G, Singh Y, Cannet C, Reinsperger T, Schäfer H, Spraul M, Kneilling
685 M, Merle U, Trautwein C. Quantitative Serum NMR Spectroscopy Stratifies COVID-19 Patients
686 and Sheds Light on Interfaces of Host Metabolism and the Immune Response with Cytokines and
687 Clinical Parameters. *Metabolites.* 2022; 12(12):1277. doi: 10.3390/metabo12121277
- 688
- 689 22. Ambikan AT, Yang H, Krishnan S, Svensson AS, Gupta S, Lourda M, et al. Multi-omics
690 personalized network analyses highlight progressive disruption of central metabolism associated
691 with COVID-19 severity. *Cell Syst.* 2022;13(8):665-681.e4. doi: 10.1016/j.cels.2022.06.006.
- 692

- 693 23. Lionetto L, Ulivieri M, Capi M, De Bernardini D, Fazio F, Petrucca, A; et al. Increased
694 kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An
695 observational cohort study. *Biochim Biophys Acta Mol Basis Dis.* 2021; 1867(3): 166042. Doi:
696 10.1016/j.bbadis.2020.166042
697
- 698 24. Occelli C, Guignonis JM, Lindenthal S, Cagnard A, Graslin F, Brglez V, et al. Untargeted plasma
699 metabolomic fingerprinting highlights several biomarkers for the diagnosis and prognosis of
700 coronavirus disease 19. *Front Med (Lausanne).* 2022; 29(9):995069. doi:
701 10.3389/fmed.2022.995069.
702
- 703 25. Herrera Oostdam AS, Castañeda-Delgado JE, Oropeza-Valdez JJ, Borrego JC, Monárrez-
704 Espino J, Zheng J, et al. Immunometabolic signatures predict risk of progression to sepsis in
705 COVID-19. *PLoS One.* 2021;16(8):e0256784. doi: 10.1371/journal.pone.0256784.
706
- 707 26. Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. COVID-19
708 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status.
709 *JCI Insight.* 2020; 23, 5(14):e140327. doi: 10.1172/jci.insight.140327.
710
- 711 27. Zhang Y, Guo R, Kim SH, Shah H, Zhang S, Liang JH, et al. SARS-CoV-2 hijacks folate and
712 one-carbon metabolism for viral replication. *Nat Commun.* 2021; 12, 1676. doi:
713 doi.org/10.1038/s41467-021-21903-z
714
- 715 28. Hwang TL, Shaka AJ. Water suppression that works. Excitation sculpting using arbitrary
716 wave-forms and pulsed-field gradients. *J Magn Reson.* 1995; 112 (2): 275-279. doi:
717 10.1006/jmra.1995.1047
718
- 719 29. Carr HY, Purcell EM. Effects of Diffusion on Free Precession in Nuclear Magnetic Resonance
720 Experiments. *Phys Rev.* 1954; 94: 630–638. doi: 10.1103/PhysRev.94.630
721
- 722 30. Ludwig C, Günther UL. MetaboLab - advanced NMR data processing and analysis for
723 metabolomics. *BMC Bioinformatics.* 2011; 12, 366. doi:10.1186/1471-2105-12-366
724
- 725 31. Parsons HM, Ludwig C, Günther UL, Viant MR. Improved classification accuracy in 1- and
726 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm
727 transformation. *BMC Bioinformatics.* 2007; 8, 234. doi: 10.1186/1471-2105-8-234
728
- 729 32. Bingol K, Li DW, Bruschweiler-Li L, Cabrera AO, Megraw T, Zhang F, et al. Unified and
730 Isomer-Specific NMR Metabolomics Database for the Accurate Analysis of 13 C– 1 H HSQC
731 Spectra. *ACS Chem Biol.* 2015; 10 (2):452–459. doi: 10.1021/cb5006382
732
- 733 33. Robinette SL, Zhang F, Bruschweiler-Li L, Bruschweiler R. Web Server Based Complex
734 Mixture Analysis by NMR. *Anal Chem.* 2008; 80 (10):3606–3611. doi: 10.1021/ac702530t
735
- 736 34. Ulrich EL, Akutsu H, Doreleijers JF, Harano Y, Ioannidis YE, Lin J, et al. BioMagResBank.
737 *Nucleic Acids Res.* 2007; 36 (1):D402–408. doi: 10.1093/nar/gkm957
738

- 739 35. Wishart, D.S.; Feunang, Y.D.; Marcu, A.; Guo, A.C.; Liang, K.; Vázquez-Fresno, R. et al.
740 HMDB 4.0: the human metabolome database for 2018. *Nucleic Acids Res.* 2018; 46 (D1): D608–
741 D617.
742
- 743 36. Kirwan JA, Gika H, Beger RD, Bearden D, Dunn WB, Goodacre R, et al. Quality assurance
744 and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for
745 analytical quality management. *Metabolomics.* 2022;18, 70. doi: 10.1007/s11306-022-01926-3.
746
- 747 37. Tsugawa H, Cajka T, Kind T, Ma Y, Higgins B, Ikeda K, et al. MS-DIAL: data-independent
748 MS/MS deconvolution for comprehensive metabolome analysis. *Nat. Methods.* 2015; 12: 523–
749 526. doi: 10.1038/nmeth.3393
750
- 751 38. Dunn WB, Broadhurst D, Begley P, et al. Procedures for large-scale metabolic profiling of
752 serum and plasma using gas chromatography and liquid chromatography coupled to mass
753 spectrometry. *Nat. Protoc.* 2011; 6 (7):1060–1083. doi: 10.1038/nprot.2011.335.
754
- 755 39. Tsugawa H, Kind T, Nakabayashi R, Yukihiro D, Tanaka W, Cajka T, et al. Hydrogen
756 Rearrangement Rules: Computational MS/MS Fragmentation and Structure Elucidation Using
757 MS-FINDER Software. *Anal. Chem.* 2016; 88 (16): 7946–7958.
758
- 759 40. Broadhurst D, Goodacre R, Reinke SN, Kuligowski J, Wilson ID, Lewis MR, Dunn WB.
760 Guidelines and considerations for the use of system suitability and quality control samples in mass
761 spectrometry assays applied in untargeted clinical metabolomic studies. *Metabolomics.*
762 2018;14(6):72. doi: 10.1007/s11306-018-1367-3.
763
- 764 41. Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative
765 Metabolomics Data Analysis. *Cur Protoc Bioinformatics.* 2019; 68(1):e86.doi: 10.1002/cpbi.86.
766
- 767 42. Breiman L, Friedman JH, Olshen RA, Stone CJ. *Classification and Regression Trees*;
768 Routledge: New York, NY, 2017. 368 p.
769
- 770 43. Therneau T, Atkinson B, port BR (producer of the initial R, maintainer 1999-2017). *rpart*:
771 Recursive Partitioning and Regression Trees 2022.
772
- 773 44. Ament Z, Bevers MB, Wolcott Z, Kimberly WT, Acharjee A. Uric Acid and Gluconic Acid as
774 Predictors of Hyperglycemia and Cytotoxic Injury after Stroke. *Transl Stroke Res.* 2021; 12 (2):
775 293–302. doi: 10.1007/s12975-020-00862-5
776
- 777 45. Li T, Ning N, Li B, Luo D, Qin E, Yu W, Wang J, Yang G, Nan N, He Z, Yang N, Gong S, Li
778 J, Liu A, Sun Y, Li Z, Jia T, Gao J, Zhang W, Huang Y, Hou J, Xue Y, Li D, Wei Z, Zhang L, Li
779 B, Wang H. Longitudinal Metabolomics Reveals Ornithine Cycle Dysregulation Correlates With
780 Inflammation and Coagulation in COVID-19 Severe Patients. *Front Microbiol.* 2021 Dec
781 3;12:723818. doi: 10.3389/fmicb.2021.723818.
782

- 783 46. Wen D, Zheng Z, Surapaneni A, Yu B, Zhou L, Zhou W, et al. Metabolite profiling of CKD
784 progression in the chronic renal insufficiency cohort study. *JCI Insight*. 2022; 24,7(20):e161696.
785 doi: 10.1172/jci.insight.161696.
786
- 787 47. Correia BSB, Ferreira VG, Piagge PMFD, Almeida MB, Assunção NA, Raimundo JRS, et
788 al. ¹H qNMR-Based Metabolomics Discrimination of Covid-19 Severity. *J Proteome Res*. 2022;
789 21, (7):1640-1653. <https://doi.org/10.1021/acs.jproteome.1c00977>
790
- 791 48. Kazak L, Rahbani JF, Samborska B, Lu GZ, Jedrychowski MP, Lajoie M, et al. Ablation of
792 adipocyte creatine transport impairs thermogenesis and causes diet-induced obesity. *Nat Metab*.
793 2019, 1, 360-370. doi: 10.1021/acs.jproteome.1c00977
794
- 795 49. Kazak L, Cohen P. Creatine metabolism: energy homeostasis, immunity and cancer biology.
796 *Nat Rev Endocrinol*. 2020; 16(8):421-436. doi: 10.1038/s41574-020-0365-5
797
- 798 50. Hu, S.; He, W.; Wu, G. Hydroxyproline in animal metabolism, nutrition, and cell signalling.
799 *Amino Acids*. 2022; 54(4): 513–528. doi: 10.1007/s00726-021-03056-x
800
- 801 51. Ducker GS, Rabinowitz JD. One-Carbon Metabolism in Health and Disease. *Cell Metab*. 2017;
802 25(1): 27–42. doi: 10.1016/j.cmet.2016.08.009
803
- 804 52. Van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of
805 phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. *Biochim*
806 *Biophys Acta Biomembr*. 2017, 1859, 1558–1572.
807
- 808 53. Silva RP, Eudy BJ, Deminice R. One-Carbon Metabolism in Fatty Liver Disease and Fibrosis:
809 One-Carbon to Rule Them All. *J Nutr*. 2020; 150 (5): 994–1003. doi:10.1093/jn/nxaa032
810
- 811 54. Teixeira L, Temerozo JR, Pereira-Dutra FS, Ferreira AC, Mattos M, Gonçalves BS et al.
812 Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral
813 Infection Through Disruption of Lipid Rafts. *Front Immunol*. 2022, 13, 820131.
814
- 815 55. Lodge S, Nitschke P, Kimhofer T, Coudert JD, Begum S, Bong SH, et al. NMR Spectroscopic
816 Windows on the Systemic Effects of SARS-CoV-2 Infection on Plasma Lipoproteins and
817 Metabolites in Relation to Circulating Cytokines. *J Proteome Res*. 2021;20(2):1382-1396. doi:
818 10.1021/acs.jproteome.0c00876.
819
- 820 56. Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C. et al. Plasma metabolomic and lipidomic
821 alterations associated with COVID-19. *Natl Sci Rev*. 2020; 7(7): 1157–1168. doi:
822 10.1093/nsr/nwaa086
823
- 824 57. Roberts AB, Gu X, Buffa JA, Hurd AG, Wang Z, Zhu, W. et al. Development of a gut microbe-
825 targeted nonlethal therapeutic to inhibit thrombosis potential. *Nat Med*. 2018; 24(9):1407–1417.
826 doi: 10.1038/s41591-018-0128-1
827

- 828 58. Yang S, Li X, Yang F, Zhao R, Pan X, Liang J, et al. Gut Microbiota-Dependent Marker
829 TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and
830 Potential as a Therapeutic Target. *Front Pharmacol.* 2019; 10:1360. doi:
831 10.3389/fphar.2019.01360
832
- 833 59. Manolis AS, Manolis TA, Manolis AA, Papatheou D, Melita H. COVID-19 Infection: Viral
834 Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic
835 Management. *J Cardiovasc Pharmacol Ther.* 2021; 26(1): 12–24. doi:
836 10.1177/1074248420958973
837
- 838 60. Bennett JA, Mastrangelo MA, Ture SK, Smith CO, Loelius SG, Berg RA, et al. The choline
839 transporter Slc44a2 controls platelet activation and thrombosis by regulating mitochondrial
840 function. *Nat Commun.* 2020; 11, 3479. doi: 10.1038/s41467-020-17254-w
841
- 842 61. Sibal L, Agarwal SC, Home PD, Boger RH. The Role of Asymmetric Dimethylarginine
843 (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. *Curr Cardiol Rev.* 2010; 6 (2):
844 82–90. doi: 10.2174/157340310791162659
845
- 846 62. Zhao WC, Li G, Huang CY, Jiang JL. Asymmetric dimethylarginine: An crucial regulator in
847 tissue fibrosis. *Eur J Pharmacol.* 2019; 854, 54–61. doi: 10.1016/j.ejphar.2019.03.055.
848
- 849 63. Ren W, Rajendran R, Zhao Y, Tan B, Wu G, Bazer FW, et al. Amino Acids As Mediators of
850 Metabolic Cross Talk between Host and Pathogen. *Front Immunol.* 2018; 9, 319. doi:
851 10.3389/fimmu.2018.00319
852
- 853 64. Li P, Yin YL, Li D, Kim SW, Wu G. Amino acids and immune function. *Br J Nutr.* 2007, 98
854 (2): 237–252. doi: 10.1017/S000711450769936X
855
- 856 65. Thiele I, Fleming RMT. Whole-body metabolic modelling predicts isoleucine dependency of
857 SARS-CoV-2 replication. *Comput Struct Biotechnol J.* 2022; 20: 4098–4109. doi:
858 10.1016/j.csbj.2022.07.019
859
- 860 66. Oliveira LG, de Souza YA, Yamamoto P, Carregari VC, Crunfli F, Reis-de-Oliveira G, et al.
861 SARS-CoV-2 infection impacts carbon metabolism and depends on glutamine for replication in
862 Syrian hamster astrocytes. *J Neurochem.* 2022; 163(2): 113-132.
863
- 864 67. Páez-Franco JC, Maravillas-Montero JL, Mejía-Domínguez NR, Torres-Ruiz J, Tamez-Torres
865 KM, Pérez-Fragoso A. Metabolomics analysis identifies glutamic acid and cystine imbalances in
866 COVID-19 patients without comorbid conditions. Implications on redox homeostasis and COVID-
867 19 pathophysiology. *PLoS One.* 2022; 17(9):e0274910. doi: 10.1371/journal.pone.0274910.
868
- 869 68. Frampas CF, Longman K, Spick M, Lewis HM, Costa CDS, Stewart A, et al. Untargeted saliva
870 metabolomics by liquid chromatography-Mass spectrometry reveals markers of COVID-19
871 severity. *PLoS One.* 2022;17(9):e0274967. doi: 10.1371/journal.pone.0274967.
872

- 873 69. Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for “acute-phase”
874 glycoproteins in high resolution proton NMR spectra of human blood plasma. *FEBS Lett.* 1987;
875 215(2): 311–315. doi: 10.1016/0014-5793(87)80168-0
876
- 877 70. Holmes E, Nicholson JK, Lodge S, Nitschke P, Kimhofer T, Wist J. Diffusion and relaxation
878 edited proton NMR spectroscopy of plasma reveals a high-fidelity supramolecular biomarker
879 signature of SARS-CoV-2 infection. *Analytical Chemistry.* 2021; 93(8): 3976–3986.
880 <https://doi.org/10.1021/acs.analchem.0c04952>.
881
- 882 71. Lipman D, Safo SE, Chekouo T. Multi-omic analysis reveals enriched pathways associated
883 with COVID-19 and COVID-19 severity. *PLoS One.* 2022;17(4):e0267047. doi:
884 10.1371/journal.pone.0267047.
885
- 886 72. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly
887 contributes to hepatic impairment in patients with COVID-19. *J Hepatol.* 2020; 73 (4): 807–816.
888 doi: 10.1016/j.jhep.2020.05.002
889
- 890 73. Lagana SM, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, et al. Hepatic pathology
891 in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic
892 data. *Mod Pathol.* 2020; 33, 2147–2155. doi: 10.1038/s41379-020-00649-x
893
- 894 74. Roberts I, Wright Muelas M, Taylor JM, Davison AS, Xu Y, Grixti JM, et al. Untargeted
895 metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity
896 and outcome. *Metabolomics.* 2021; 18, 6. doi: 10.1007/s11306-021-01859-3
897
- 898 75. Vázquez-Medina UM, Cerda-Reyes E, Galeana-Pavón A, López-Luna CE, Ramírez-Portillo
899 PM, Ibañez-Cervantes G, et al. Interaction of metabolic dysfunction-associated fatty liver disease
900 and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients
901 hospitalized with coronavirus disease 2019. *Hepatol Commun.* 2022; 6 (8): 2000–2010. doi:
902 10.1002/hep4.1957
903
- 904 76. Mooli RGR, Ramakrishnan SK. Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease.
905 *Front Physiol.* 2022; 13:946474. doi: 10.3389/fphys.2022.946474
906
- 907 77. Perazzo H, Cardoso SW, Ribeiro MPD, Moreira R, Coelho LE, Jalil EM, et al. In-hospital
908 mortality and severe outcomes after hospital discharge due to COVID-19: A prospective
909 multicenter study from Brazil. *Lancet Reg Health Am.* 2022; 11:100244. doi:
910 10.1016/j.lana.2022.100244. Erratum in: *Lancet Reg Health Am.* 2022.
911
- 912 78. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender
913 on COVID-19 outcomes in Europe. *Biol Sex Differ.* 2020; 11, 29. doi: 10.1186/s13293-020-
914 00304-9
915
- 916 79. Bechmann N, Barthel A, Schedl A, Herzig S, Varga Z, Gebhard C. et al. Sexual dimorphism
917 in COVID-19: potential clinical and public health implications. *Lancet Diabetes Endocrinol.* 2022;
918 10 (3): 221–230. doi: 10.1016/S2213-8587(21)00346-6

919 **Supporting Information Caption**

920 **Supplementary Table 1:** List of the target compounds monitored in the method at pH8.

921 **Supplementary Table 2:** List of the target compounds monitored in the method at pH3.

922 **Supplementary Table 3:** Parameters used for untargeted analysis in MS-DIAL software.

923 **Supplementary Table 4:** Assignment table of metabolites that discriminated in the PCA and
924 univariate analyses.

925 **Supplementary Table 5:** Assigned metabolites with significant differences among groups
926 according to the non-targeted MS-metabolomics in the negative mode.


927 **Supplementary Table 6:** Assigned metabolites according to the non-targeted MS-metabolomics
928 in the positive mode.

929 **Supplementary Figure 1.** PCA loading factors plot highlights discriminating metabolites
930 according to ¹H NMR-based metabolomics.

931 **Supplementary Figure 2.** PC1 scores plot versus sample in run order at pH 8 and pH 3 analyses
932 indicating the stability of the system throughout the analytical run.

933 **Supplementary Figure 3: Classification and Regression Tree (CART) model indicates that**
934 **NH₃-choline related metabolites and creatine/creatinine present high predictive power in**
935 **assigning subjects according to their morbidity class.** The CART model was built using the
936 metabolites that were found to be discriminatory in the multivariate PCA analysis, which was
937 based on ¹H NMR metabolomics: NH₃-choline-related metabolites, creatine/creatinine, glutamine,
938 alanine, histidine, tyrosine, valine, leucine, isoleucine, CH₂ of lipoproteins (VLDL), CH=CH
939 olefinic protons of triacylglycerols, acetoacetate, lactate, acetate, formate, *N*-acetyl of
940 glycoproteins. In red is the classification that best predicted the morbidity class for control subjects
941 (partition point choline ≥ 2.064), survivors - creatine/creatinine < 1.473 and non-survivors -
942 creatine/creatinine ≥ 1.473 .

943








Figure 1


one-carbon metabolism



glucose metabolism, insulin sensitivity and inflammation



lipid metabolism – lipoproteins and ketogenesis



amino acid metabolism






Figure 2


one-carbon metabolism




nucleic acid metabolism



glucose metabolism, insulin sensitivity and inflammation



ketogenesis



amino acid metabolism




Figure 3




Figure 4




Figure 5